Inqaba Biotechnical Industries (Pty) Ltd
Animal Genetics Division

Co. Reg. No: 2001/011245/07
VAT No: 4150197251

Neuronal Ceroid Lipofuscinosis (CLN5)

Client Name:	Lauriaan Morton (LAU002)	Report No:	ZO2025/9673/20250804/#101094
Client Address:	Lauriaan Morton (LAU002) 23 Egret Street Welkom, Free State 9459 South Africa		
Phone:	0768783024		
Email:	lauriaan@vodamail.co.za		
Profile:	DG2025/93667	Species:	Canis lupus familiaris / Canine / Dog
Name:	Golden Starseed Blue (Mufasa)	Microchip #:	972274200143122
Breed:	Golden Retriever		

Test:	[NCL-5 Golden Retriever] Neuronal Ceroid Lipofuscinosis (CLN5)		
Results:	c.934_935delAG	AG/AG	CLEAR

Sample Type: Whole Blood (EDTA) Extraction Method: DNA Extraction: D4069 Test Type: Genetic Health

[NCL-5 Golden Retriever] Neuronal Ceroid Lipofuscinosis (CLN5)

Neuronal Ceroid Lipofuscinosis (NCL) is a group of neurodegenerative disorders characterized by the accumulation of autofluorescent lipopigments in the nervous system. Symptoms and onset vary amongst different breeds.

The mutation characterized in the Golden Retriever breed is a deletion mutation c.934-935delAG in the CLN5 gene.

This is an autosomal recessive trait that requires two copies of the mutant allele to cause the disease.

References: Gilliam et al 2015. Golden Retriever dogs with neuronal ceroid lipofuscinosis have a two-base-pair deletion and frameshift in CLN5. Molecular Genetics and Metabolism 1832(2-3)

Disclaimer:
Whatever is contained in this report is subject to the following:

This report does not disregard the existence of any rare or unknown variant within this gene or other gene(s) that may results in the same or similar trait. Multiple mutations and/or gene(s) may contribute to the overall trait observed.

Inqaba Biotechnical Industries Pty Ltd and the divisions thereof (Registration number: 2001/011245/07) accepts that the biological specimen(s) provided, originates from the relevant animal(s) indicated on supporting documents received and does not accept responsibility for the downstream effects of incorrect information provided.

It is the responsibility of the client that all biological samples are available at submission or previously submitted and corresponds with all requested samples listed on the sample submission form. Inqaba Biotechnical Industries Pty Ltd and the divisions thereof does not accept responsibility for the effect of any absent samples on the analysis results.

Inqaba Biotechnical Industries Pty Ltd and the divisions thereof accepts that all genetic profiles and/or samples from external sources are correctly labelled and accurate. Inqaba Biotechnical Industries Pty Ltd and the divisions thereof does not accept responsibility for the effect of any inaccuracies of submitted DNA profiles on the analysis and results.

Inqaba Biotechnical Industries Pty Ltd and the divisions thereof shall not be responsible for human and/or technical errors that could not have been foreseen.

This document is solely for the use of the addressee and only in connection for the purpose set out in this document. Inqaba Biotechnical Industries Pty Ltd and the divisions thereof do not assume liability or responsibility to any third party to which this document is disclosed or otherwise made available.

Nothing in this document should be construed as advice to proceed or not to proceed with any specific course of action, as it was not prepared for that purpose.

The DNA profile is based on a preliminary marker panel that is subject to modification pending additional genetic information.

It is the sender’s responsibility to obtain permits when sending samples where required.

Inqaba Biotechnical Industries Pty Ltd and the divisions thereof reserve the right to decline testing of samples.

No guarantees are made with regards to turn-around processing time and results, and no liability will be accepted for any delays.